Resources
An Automated Variant Verification System To Improve Reporting Efficiency
Poster
Posted on Nov 21, 2024
Interpretation of neurological disorders cohort through in-house developed tool, festiVAR, showed an improved diagnostic yield: data from over 1000 Indian patients
Poster
Posted on Nov 21, 2024
Automation Of Time-Consuming WES Steps And Use Of LLMs
Poster
Posted on Nov 21, 2024
FDA Rule on Lab Developed Tests (LDTs) for Laboratories Setting Up Molecular LDTs
Solution Snapshot
Posted on Aug 29, 2024
Streamlining Germline Testing: Pipeline Development and Clinical Variant Interpretation
Case Study
Posted on Jul 17, 2024
Comprehensive End-to-End Solutions for a Pet NGS Diagnostic
Case Study
Posted on Jul 16, 2024
Exploring the Hidden Patterns: Leveraging FrAnaTk for cfDNA Fragment Analysis
Webinar
Posted on Jun 27, 2024
StrandIris: Revolutionizing Precision Oncology through Enhanced Tertiary Analysis Features
Webinar
Posted on Jun 27, 2024
Showcasing Strand’s Expertise: A Closer Look at StrandOmics
Tech Note
Posted on Jun 06, 2024
Why StrandIris?
White Paper
Posted on Jun 06, 2024
Highlighting the Expertise Behind StrandOmics: Advancing Germline and Somatic Variant Classification
Tech Note
Posted on Jun 05, 2024
Decoding Ulcerative Colitis at the Cellular Level with our Single-Cell RNA Sequencing Data Curation Portal
Poster
Posted on May 09, 2024
Strand is Spearheading Pet NGS Diagnostics
Brochure
Posted on Mar 29, 2024
Somatic Variant Database Curation
Case Study
Posted on Mar 29, 2024
A Saliva-based Liquid Biopsy Assay for Oral Cancer
Case Study
Posted on Mar 29, 2024
Provider Portal & Electronic Data Capture Portal
Case Study
Posted on Mar 29, 2024
NGS Analysis Pipeline Development
Case Study
Posted on Mar 29, 2024
Our
Featured
Publications
Clinical Chemistry
Aug 2021
Determining Cost-Optimal Next-Generation Sequencing Panels for Rare Disease and Pharmacogenomics Testing
Multi-gene panel sequencing using next-generation sequencing (NGS) methods is a key tool for genomic medicine. However, with an estimated 140,000 genomic tests available, current system inefficiencies result in high genetic-testing costs.
BMC Medical Genomics
Apr 2021
Validation of whole genome sequencing from dried blood spots
Dried blood spots (DBS) are a relatively inexpensive source of nucleic acids and are easy to collect, transport, and store in large-scale field surveys, especially in resource-limited settings. However, their performance in whole-genome sequencing (WGS) relative to that of venous blood DNA has not been analyzed for various downstream applications.
Cancer Medicine
Sep 2018
Analysis of solid tumor mutation profiles in liquid biopsy
Liquid biopsy is increasingly gaining traction as an alternative to invasive solid tumor biopsies for prognosis, treatment decisions, and disease monitoring. Matched tumor-plasma samples were collected from 180 patients across different cancers with >90% of the samples below Stage IIIB.
Breast Cancer Research and Treatment
Feb 2018
Screening of over 1000 Indian patients with breast and/or ovarian cancer with a multi-gene panel: prevalence of BRCA1/2 and non-BRCA mutations
Breast and/or ovarian cancers are among the most common cancers in women across the world. In the Indian population, the healthcare burden of breast and/or ovarian cancers has been steadily rising, thus stressing the need for early detection, surveillance, and disease management measures. However, the burden attributable to inherited mutations is not well characterized.
Cancer Medicine
Apr 2017
StrandAdvantage test for early-line and advanced-stage treatment decisions in solid tumors
Comprehensive genetic profiling of tumors using next-generation sequencing (NGS) is gaining acceptance for guiding treatment decisions in cancer care. We designed a cancer profiling test combining both deep sequencing and immunohistochemistry (IHC) of relevant cancer targets to aid therapy choices in both standard-of-care (SOC) and advanced-stage treatments for solid tumors.
download the case study.